[
    [
        {
            "time": "2019-09-16",
            "original_text": "格隆汇港股聚焦(9.16)︱中国平安前8月原保费收入升9.43%至5542亿元 中国国航8月旅客周转量同比升6.1%",
            "features": {
                "keywords": [
                    "中国平安",
                    "保费收入",
                    "中国国航",
                    "旅客周转量"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "航空"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(9.16)︱中国平安前8月原保费收入升9.43%至5542亿元 中国国航8月旅客周转量同比升6.1%",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-09-16",
            "original_text": "行业延续高景气度 低估值医药股存“秋收”机会",
            "features": {
                "keywords": [
                    "医药",
                    "景气度",
                    "低估值"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "行业延续高景气度 低估值医药股存“秋收”机会",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-09-16",
            "original_text": "上海医药(02607.HK)控股股东上实集团增持5.05万股H股",
            "features": {
                "keywords": [
                    "上海医药",
                    "上实集团",
                    "增持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(02607.HK)控股股东上实集团增持5.05万股H股",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-09-16",
            "original_text": "2019上半年，这5家药企销售费用均超32亿元",
            "features": {
                "keywords": [
                    "药企",
                    "销售费用",
                    "2019上半年"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "2019上半年，这5家药企销售费用均超32亿元",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-09-16",
            "original_text": "上海医药:销售费用攀升拖累利润增长 商誉金额超百亿 盈利能力下降",
            "features": {
                "keywords": [
                    "上海医药",
                    "销售费用",
                    "利润增长",
                    "商誉",
                    "盈利能力"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "上海医药:销售费用攀升拖累利润增长 商誉金额超百亿 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]